Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

ACC 2023 ACC.23 American College of Cardiology

American College of Cardiology announces late-breaking research for ACC.24 in Atlanta

The group's annual meeting heads to Atlanta this April. TAVR, GLP-1 agonists, medical imaging guidance and blood pressure control are just some of the topics that will be presented during late-breaking sessions.

January 29, 2024

Heart surgeons alarmed by high number of young patients choosing TAVR over SAVR

Nearly 50% of patients under the age of 60 are now opting for TAVR over SAVR, according to a new study presented at STS 2024 in San Antonio. "We owe it to our patients to take a more prominent role in providing the highest quality evidence to help our patients make these major healthcare decisions," one researcher said. 

January 28, 2024
CroíValve DUO device tricuspid valve. The DUO Tricuspid Coaptation Valve System includes both a prosthetic coaptation valve that works in tandem with the patient’s native tricuspid valve and an anchor system designed to adjust and lock the position of the coaptation valve as needed. According to CroíValve, the device “combines repair and replacement to provide the right solution for the right heart.”

CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board

The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation. 

January 25, 2024
Overview of the Tootsie Roll technique for treating paravalvular leak in certain transcatheter heart valve patients. Tootsie Roll paravalvular leak transcatheter heart valves.

New ‘Tootsie Roll’ technique could help cardiologists treat PVL in transcatheter heart valves

Paravalvular leak remains a significant problem after TAVR, SAVR and even TMVR. Could a new-look interventional technique help heart teams overcome this issue and improve patient outcomes? 

January 24, 2024
Medicare data stethoscope healthcare trends graphs finance financials

An updated look at combining LAAO with ablation, TAVR or other interventional heart procedures

Performing two procedures at once does not appear to make a significant impact on patient safety, though it may lead to a few new risks sure to interest heart teams. 

January 23, 2024
Pi-Cardia ShortCut TAVR device. According to Pi-Cardia, ShortCut is the first medical device of its kind; interventional cardiologists use it to split valve leaflets in patients who have been recommended for valve-in-valve TAVR and face a heightened coronary obstruction risk.

FDA grants new valve-in-valve TAVR offering its breakthrough device designation

The new device was designed to help clinicians perform valve-in-valve TAVR on certain high-risk patients. One cardiologist familiar with the technology said it could be easily added to any preexisting TAVR workflow. 

January 23, 2024
older patient with a doctor at their house

Valve-in-valve TAVR with Medtronic’s CoreValve devices still safe and effective after 5 years

Researchers tracked five-year data from more than 200 patients, sharing their findings in the American Journal of Cardiology.

January 22, 2024
weight loss scale overweight obese lose weight pounds

TAVR in patients with severe obesity: Longer hospital stays, higher costs, more health risks

The CDC defines severe obesity, or class III obesity, as any patient with a BMI of 40 or higher. TAVR among these patients is not associated with a lower survival rate, but it does lead to many more risks.

January 19, 2024

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup